Advanced search
Publication Cover
Immunotherapy Volume 3, 2011 - Issue 2
Submit an article Journal homepage
3,290
Views
2
CrossRef citations to date
0
Altmetric
Review

Small-Molecule Protein Kinase Inhibitors and Their Effects on the Immune System: Implications for Cancer Treatment

Patrick A Ott1 New York University Cancer Institute, Division of Medical Oncology, 160 E 34th Street, New York, NY10016, USACorrespondence[email protected]
&
Sylvia Adams1 New York University Cancer Institute, Division of Medical Oncology, 160 E 34th Street, New York, NY10016, USA
Pages 213-227 | Published online: 15 Feb 2011

Bibliography

  • Dunn GP , BruceAT, IkedaH, OldLJ, SchreiberRD: Cancer immunoediting: from immunosurveillance to tumor escape.Nat. Immunol.3(11) , 991–998 (2002).
  • Zou W : Immunosuppressive networks in the tumour environment and their therapeutic relevance.Nat. Rev. Cancer5(4) , 263–274 (2005).
  • Lurquin C , LetheB, De Plaen E et al.: Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a mage tumor antigen. J. Exp. Med.201(2) , 249–257 (2005).
  • Peterson AC , HarlinH, GajewskiTF: Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.J. Clin. Oncol.21(12) , 2342–2348 (2003).
  • Rosenberg SA , SherryRM, MortonKE et al.: Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.J. Immunol.175(9) , 6169–6176 (2005).
  • Yuan J , GnjaticS, LiH et al.: CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T-cell responses in metastatic melanoma patients with clinical benefit.Proc. Natl Acad. Sci. USA105(51) , 20410–20415 (2008).
  • Atkins MB , LotzeMT, DutcherJP et al.: High-dose recombinant IL-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.J. Clin. Oncol.17(7) , 2105–2116 (1999).
  • Hodi FS , O‘DaySJ, McDermottDF et al.: Improved survival with ipilimumab in patients with metastatic melanoma.N. Engl. J. Med.363(8) , 711–723 (2010).
  • De Souza AP , BonorinoC: Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses.Expert Rev. Anticancer Ther.9(9) , 1317–1332 (2009).
  • Flavell RA , SanjabiS, WrzesinskiSH, Licona-LimonP: The polarization of immune cells in the tumour environment by TGFb.Nat. Rev. Immunol.10 , 554–567 (2010).
  • Burdelya L , KujawskiM, NiuG et al.: STAT3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects.J. Immunol.174(7) , 3925–3931 (2005).
  • Nefedova Y , ChengP, GilkesD et al.: Activation of dendritic cells via inhibition of JAK2/STAT3 signaling.J. Immunol.175(7) , 4338–4346 (2005).
  • Nefedova Y , HuangM, KusmartsevS et al.: Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer.J. Immunol.172(1) , 464–474 (2004).
  • Sumimoto H , ImabayashiF, IwataT, KawakamiY: The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.J. Exp. Med.203(7) , 1651–1656 (2006).
  • Alvarez RH , ValeroV, HortobagyiGN: Emerging targeted therapies for breast cancer.J. Clin. Oncol.28(20) , 3366–3379 (2010).
  • Fecher LA , AmaravadiRK, SchuchterLM, FlahertyKT: Drug targeting of oncogenic pathways in melanoma.Hematol. Oncol. Clin. North Am.23(3) , 599–618 (2009).
  • Calne RY , CollierDS, LimS et al.: Rapamycin for immunosuppression in organ allografting.Lancet2(8656) , 227 (1989).
  • Neuhaus P , KluppJ, LangrehrJM: mTOR inhibitors: an overview.Liver Transpl.7(6) , 473–484 (2001).
  • Powell JD , LernerCG, SchwartzRH: Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation.J. Immunol.162(5) , 2775–2784 (1999).
  • Vanasek TL , KhorutsA, ZellT, MuellerDL: Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness.J. Immunol.167(10) , 5636–5644 (2001).
  • Zheng Y , CollinsSL, LutzMA et al.: A role for mammalian target of rapamycin in regulating T-cell activation versus anergy.J. Immunol.178(4) , 2163–2170 (2007).
  • Delgoffe GM , KoleTP, ZhengY et al.: The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment.Immunity30(6) , 832–844 (2009).
  • Kang J , HuddlestonSJ, FraserJM, KhorutsA: De novo induction of antigen-specific CD4+CD25+foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR.J. Leukoc. Biol.83(5) , 1230–1239 (2008).
  • Battaglia M , StabiliniA, RoncaroloMG: Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells.Blood105(12) , 4743–4748 (2005).
  • Strauss L , WhitesideTL, KnightsA, BergmannC, KnuthA, ZippeliusA: Selective survival of naturally occurring human CD4+CD25+FoxP3+ regulatory T cells cultured with rapamycin.J. Immunol.178(1) , 320–329 (2007).
  • Thomson AW , TurnquistHR, RaimondiG: Immunoregulatory functions of mTOR inhibition.Nat. Rev. Immunol.9(5) , 324–337 (2009).
  • Turnquist HR , RaimondiG, ZahorchakAF, FischerRT, WangZ, ThomsonAW: Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific FoxP3+ T regulatory cells and promote organ transplant tolerance.J. Immunol.178(11) , 7018–7031 (2007).
  • Hackstein H , TanerT, LogarAJ, ThomsonAW: Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells.Blood100(3) , 1084–1087 (2002).
  • Hackstein H , TanerT, ZahorchakAF et al.: Rapamycin inhibits IL-4 induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo.Blood101(11) , 4457–4463 (2003).
  • Monti P , MercalliA, LeoneBE, ValerioDC, AllavenaP, PiemontiL: Rapamycin impairs antigen uptake of human dendritic cells.Transplantation75(1) , 137–145 (2003).
  • Gulen MF , KangZ, BulekK et al.: The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation.Immunity32(1) , 54–66 (2010).
  • Donahue AC , FrumanDA: Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli.Eur. J. Immunol.37(10) , 2923–2936 (2007).
  • Heidt S , RoelenDL, EijsinkC, Van Kooten C, Claas FH, Mulder A: Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. Transplantation86(9) , 1292–1300 (2008).
  • Wai LE , FujikiM, TakedaS, MartinezOM, KramsSM: Rapamycin, but not cyclosporine or fk506, alters natural killer cell function.Transplantation85(1) , 145–149 (2008).
  • De Paulis A , CirilloR, CiccarelliA, De Crescenzo G, Oriente A, Marone G: Characterization of the anti-inflammatory effect of FK-506 on human mast cells. J. Immunol.147(12) , 4278–4285 (1991).
  • Ohtani M , NagaiS, KondoS et al.: Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced IL-12 production in dendritic cells.Blood112(3) , 635–643 (2008).
  • Weichhart T , CostantinoG, PoglitschM et al.: The TSC–mTOR signaling pathway regulates the innate inflammatory response.Immunity29(4) , 565–577 (2008).
  • Rao RR , LiQ, OdunsiK, ShrikantPA: The mTOR kinase determines effector versus memory CD8+ T-cell fate by regulating the expression of transcription factors T-bet and eomesodermin.Immunity32(1) , 67–78 (2010).
  • Guiducci C , GhirelliC, Marloie-ProvostMA et al.: PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation.J. Exp. Med.205(2) , 315–322 (2008).
  • Aksoy E , Vanden Berghe W, Detienne S et al.: Inhibition of phosphoinositide 3-kinase enhances TRIF-dependent NF-κB activation and IFN-β synthesis downstream of Toll-like receptor 3 and 4. Eur. J. Immunol.35(7) , 2200–2209 (2005).
  • Fukao T , TanabeM, TerauchiY et al.: PI3K-mediated negative feedback regulation of IL-12 production in DCs.Nat. Immunol.3(9) , 875–881 (2002).
  • Guha M , MackmanN: The phosphatidylinositol 3-kinase–AKT pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells.J. Biol. Chem.277(35) , 32124–32132 (2002).
  • Williams DL , LiC, HaT et al.: Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis.J. Immunol.172(1) , 449–456 (2004).
  • Polumuri SK , ToshchakovVY, VogelSN: Role of phosphatidylinositol-3 kinase in transcriptional regulation of TLR-induced IL-12 and IL-10 by Fc γ receptor ligation in murine macrophages.J. Immunol.179(1) , 236–246 (2007).
  • Arrighi JF , RebsamenM, RoussetF, KindlerV, HauserC: A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-α, and contact sensitizers.J. Immunol.166(6) , 3837–3845 (2001).
  • Lu HT , YangDD, WyskM et al.: Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (MKK3)-deficient mice.EMBO J.18(7) , 1845–1857 (1999).
  • Yoshimura S , BondesonJ, FoxwellBM, BrennanFM, FeldmannM: Effective antigen presentation by dendritic cells is NF-κB dependent: coordinate regulation of MHC, costimulatory molecules and cytokines.Int. Immunol.13(5) , 675–683 (2001).
  • Puig-Kroger A , RellosoM, Fernandez-CapetilloO et al.: Extracellular signal-regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells.Blood98(7) , 2175–2182 (2001).
  • Agrawal A , DillonS, DenningTL, PulendranB: Erk1-/- mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephalomyelitis.J. Immunol.176(10) , 5788–5796 (2006).
  • Sato K , NagayamaH, TadokoroK, JujiT, TakahashiTA: Extracellular signal-regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38MAPK are involved in IL-10-mediated selective repression of TNF-α-induced activation and maturation of human peripheral blood monocyte-derived dendritic cells.J. Immunol.162(7) , 3865–3872 (1999).
  • Ardeshna KM , PizzeyAR, DevereuxS, KhwajaA: The PI3 kinase, p38 sap kinase, and NF-κB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells.Blood96(3) , 1039–1046 (2000).
  • Escors D , LopesL, LinR et al.: Targeting dendritic cell signaling to regulate the response to immunization.Blood111(6) , 3050–3061 (2008).
  • Dong C , Davis Rj, Flavell RA: MAP kinases in the immune response. Annu. Rev. Immunol.20 , 55–72 (2002).
  • Alberola-Ila J , ForbushKA, SegerR, KrebsEG, PerlmutterRM: Selective requirement for MAP kinase activation in thymocyte differentiation.Nature373(6515) , 620–623 (1995).
  • Stefanova I , HemmerB, VergelliM, MartinR, BiddisonWE, GermainRN: TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways.Nat. Immunol.4(3) , 248–254 (2003).
  • Tan AH , LamKP: Pharmacologic inhibition of MEK–ERK signaling enhances Th17 differentiation.J. Immunol.184(4) , 1849–1857 (2010).
  • Hicklin DJ , EllisLM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.J. Clin. Oncol.23(5) , 1011–1027 (2005).
  • Forsythe JA , JiangBH, IyerNV et al.: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.Mol. Cell Biol.16(9) , 4604–4613 (1996).
  • Shchors K , EvanG: Tumor angiogenesis: cause or consequence of cancer?Cancer Res.67(15) , 7059–7061 (2007).
  • Tang N , WangL, EskoJ et al.: Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis.Cancer Cell6(5) , 485–495 (2004).
  • Ellis LM , FidlerIJ: Angiogenesis and metastasis.Eur. J. Cancer32A(14) , 2451–2460 (1996).
  • Gabrilovich D , IshidaT, OyamaT et al.: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo.Blood92(11) , 4150–4166 (1998).
  • Gabrilovich DI , ChenHL, GirgisKR et al.: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.Nat. Med.2(10) , 1096–1103 (1996).
  • Gabrilovich DI , NagarajS: Myeloid-derived suppressor cells as regulators of the immune system.Nat. Rev. Immunol.9(3) , 162–174 (2009).
  • Gabrilovich DI , IshidaT, NadafS, OhmJE, CarboneDP: Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.Clin. Cancer Res.5(10) , 2963–2970 (1999).
  • Varney ML , JohanssonSL, SinghRK: Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: role of monocyte chemotactic protein-1 and vascular endothelial growth factor-α.Melanoma Res.15(5) , 417–425 (2005).
  • Ueno T , ToiM, SajiH et al.: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.Clin. Cancer Res.6(8) , 3282–3289 (2000).
  • Solinas G , GermanoG, MantovaniA, AllavenaP: Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation.J. Leukoc. Biol.86(5) , 1065–1073 (2009).
  • Paik S , ShakS, TangG et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.N. Engl. J. Med.351(27) , 2817–2826 (2004).
  • Ohm JE , GabrilovichDI, SempowskiGD et al.: VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.Blood101(12) , 4878–4886 (2003).
  • Li B , LalaniAS, HardingTC et al.: Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.Clin. Cancer Res.12(22) , 6808–6816 (2006).
  • Huang Y , ChenX, Dikov Mm et al.: Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood110(2) , 624–631 (2007).
  • Fricke I , MirzaN, DupontJ et al.: Vascular endothelial growth factor-TRAP overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses.Clin. Cancer Res.13(16) , 4840–4848 (2007).
  • Escudier B , EisenT, StadlerWM et al.: Sorafenib in advanced clear-cell renal-cell carcinoma.N. Engl. J. Med.356(2) , 125–134 (2007).
  • Llovet JM , RicciS, MazzaferroV et al.: Sorafenib in advanced hepatocellular carcinoma.N. Engl. J. Med.359(4) , 378–390 (2008).
  • Motzer RJ , HutsonTE, TomczakP et al.: Sunitinib versus interferon-α in metastatic renal-cell carcinoma.N. Engl. J. Med.356(2) , 115–124 (2007).
  • Maemondo M , InoueA, KobayashiK et al.: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.N. Engl. J. Med.362(25) , 2380–2388 (2010).
  • Hodi FS , FriedlanderP, CorlessCL et al.: Major response to imatinib mesylate in KIT-mutated melanoma.J. Clin. Oncol.26(12) , 2046–2051 (2008).
  • Lutzky J , BauerJ, BastianBC: Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.Pigment Cell Melanoma Res.21(4) , 492–493 (2008).
  • Boissel N , RousselotP, RaffouxE et al.: Imatinib mesylate minimally affects BCR–ABL+ and normal monocyte-derived dendritic cells but strongly inhibits T-cell expansion despite reciprocal dendritic cell–T cell activation.J. Leukoc. Biol.79(4) , 747–756 (2006).
  • Dietz AB , SouanL, KnutsonGJ, BulurPA, LitzowMR, Vuk-PavlovicS: Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo.Blood104(4) , 1094–1099 (2004).
  • Cwynarski K , LaylorR, MacchiaruloE et al.: Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.Leukemia18(8) , 1332–1339 (2004).
  • Seggewiss R , LoreK, GreinerE et al.: Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.Blood105(6) , 2473–2479 (2005).
  • Mumprecht S , MatterM, PavelicV, OchsenbeinAF: Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections.Blood108(10) , 3406–3413 (2006).
  • Mattiuzzi GN , CortesJE, TalpazM et al.: Development of varicella-zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.Clin. Cancer Res.9(3) , 976–980 (2003).
  • Gao H , LeeBN, TalpazM et al.: Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia.Leukemia19(11) , 1905–1911 (2005).
  • Zipfel PA , ZhangW, QuirozM, PendergastAM: Requirement for ABL kinases in T cell receptor signaling.Curr. Biol.14(14) , 1222–1231 (2004).
  • Larmonier N , JanikashviliN, LacasseCJ et al.: Imatinib mesylate inhibits CD4+ CD25+ regulatory T-cell activity and enhances active immunotherapy against BCR–ABL-tumors.J. Immunol.181(10) , 6955–6963 (2008).
  • Agosti V , CorbaciogluS, EhlersI et al.: Critical role for KIT-mediated Src kinase but not PI 3-kinase signaling in pro T- and pro B-cell development.J. Exp. Med.199(6) , 867–878 (2004).
  • Chen CI , MaeckerHT, LeePP: Development and dynamics of robust T-cell responses to CML under imatinib treatment.Blood111(11) , 5342–5349 (2008).
  • Appel S , BoehmlerAM, GrunebachF et al.: Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.Blood103(2) , 538–544 (2004).
  • Appel S , RupfA, Weck Mm et al.: Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-κB and Akt signaling pathways. Clin. Cancer Res.11(5) , 1928–1940 (2005).
  • Mohty M , JourdanE, MamiNB et al.: Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia.Blood103(12) , 4666–4668 (2004).
  • Taieb J , MaruyamaK, BorgC, TermeM, ZitvogelL: Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo.Blood103(5) , 1966–1967; author reply 1967 (2004).
  • Wang H , ChengF, CuencaA et al.: Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance.Blood105(3) , 1135–1143 (2005).
  • Wehner R , WendischM, SchakelK et al.: Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells.Leukemia20(9) , 1629–1632 (2006).
  • Borg C , TermeM, TaiebJ et al.: Novel mode of action of c-KIT tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.J. Clin. Invest.114(3) , 379–388 (2004).
  • Mignot G , UllrichE, BonmortM et al.: The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2.J. Immunol.180(10) , 6477–6483 (2008).
  • Smyth MJ : Imatinib mesylate – uncovering a fast track to adaptive immunity.N. Engl. J. Med.354(21) , 2282–2284 (2006).
  • Van Dongen M , SavageND, JordanovaES et al.: Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors.Int. J. Cancer127(4) , 899–909 (2010).
  • Rini B i: Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin. Cancer Res.14(5) , 1286–1290 (2008).
  • Carlomagno F , AnagantiS, GuidaT et al.: Bay 43–9006 inhibition of oncogenic RET mutants.J. Natl Cancer Inst.98(5) , 326–334 (2006).
  • Wilhelm SM , CarterC, TangL et al.: Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res.64(19) , 7099–7109 (2004).
  • Hipp MM , HilfN, WalterS et al.: Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.Blood111(12) , 5610–5620 (2008).
  • Alfaro C , SuarezN, GonzalezA et al.: Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.Br. J. Cancer100(7) , 1111–1119 (2009).
  • Molhoek KR , McskimmingCC, OlsonWC, BrautiganDL, SlingluffCL Jr: Apoptosis of CD4+CD25high T cells in response to sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunol. Immunother.58(6) , 867–876 (2009).
  • Zhao W , GuYH, SongR, QuBQ, XuQ: Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation.Leukemia22(6) , 1226–1233 (2008).
  • Houben R , VoigtH, NoelkeC, HofmeisterV, BeckerJC, SchramaD: MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib.Mol. Cancer Ther.8(2) , 433–440 (2009).
  • Motzer RJ , RiniBI, BukowskiRM et al.: Sunitinib in patients with metastatic renal cell carcinoma.JAMA295(21) , 2516–2524 (2006).
  • Finke JH , RiniB, IrelandJ et al.: Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.Clin. Cancer Res.14(20) , 6674–6682 (2008).
  • Ko JS , ZeaAH, RiniBI et al.: Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.Clin. Cancer Res.15(6) , 2148–2157 (2009).
  • Ko JS , RaymanP, IrelandJ et al.: Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.Cancer Res.70(9) , 3526–3536 (2010).
  • Van Cruijsen H , Van Der Veldt AA, Vroling L et al.: Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin. Cancer Res.14(18) , 5884–5892 (2008).
  • Ozao-Choy J , MaG, KaoJ et al.: The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.Cancer Res.69(6) , 2514–2522 (2009).
  • Xin H , ZhangC, HerrmannA, DuY, FiglinR, YuH: Sunitinib inhibition of STAT3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.Cancer Res.69(6) , 2506–2513 (2009).
  • Sinai P , BergRE, HaynieJM, EgorinMJ, IlariaRL Jr, Forman J: Imatinib mesylate inhibits antigen-specific memory CD8 T-cell responses in vivo. J. Immunol.178(4) , 2028–2037 (2007).
  • Chapman P Pi, Sosman J et al.: Early efficacy signal demonstrated in advanced melanoma in a Phase I trial of the oncogenic BRAF-selective inhibitor PLX4032. Eur. J. Cancer7(3) , 5 (2009).
  • Flaherty K , PuzanovI, SosmanJ et al.: Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer.J. Clin. Oncol.27(Suppl. 15), Abstract 9000 (2009).
  • Seliger B , MassaC, RiniB, KoJ, FinkeJ: Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors.Trends Mol. Med.16(4) , 184–192 (2010).
  • Boni A , CogdillAP, DangP et al.: Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.Cancer Res.70(13) , 5213–5219 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.